Economy · World
Novo Nordisk Shares Fall on Growth Strategy Amid Competition
Novo Nordisk's shares experienced a significant decline as the company presented its growth strategy for the period following the success of its drug Wegovy. Investors reportedly sought more robust sales targets, indicating a lack of conviction in the company's future plans despite its efforts to develop new drugs to compete with rivals like Lilly.
How outlets across the spectrum covered it
L 0 C 6 R 0
- Centre (6): Bloomberg, CNBC, Financial Times, Reuters, The Economic Times, The Wall Street Journal